Promoted Content
Promoted Content

Find Oncology Drugs in Phase I Clinical Development in GERMANY

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): UniCAR-T-PSMA

            Therapeutic Area: Oncology Product Name: UniCAR-T-PSMA

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 03, 2020

            Details:

            GEMoaB has apheresed the first patient in a Phase IA study with UniCAR-T-PSMA, the lead solid tumor product candidate from its proprietary UniCAR cellular immunotherapy platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AFM13,Pembrolizumab

            Therapeutic Area: Oncology Product Name: AFM13

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            The results demonstrate promising signs of efficacy including an objective response rate of 88% at the highest treatment dose of AFM13 with KEYTRUDA, as well as a complete CR of 46%. As a monotherapy, KEYTRUDA demonstrated an ORR of 69% and a CR of 22.4% in the KEYNOTE-087.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMA101

            Therapeutic Area: Oncology Product Name: IMA101

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            ACTolog® demonstrates feasibility of a multi-target multi-T cell product approach. The target positivity rate of 90% demonstrated that such a multi-target approach leads to minimal patient attrition during screening due to lack of target expression.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AFM13-NK cells,Cyclophosphamide,Fludarabine Phosphate

            Therapeutic Area: Oncology Product Name: AFM13-NK cells

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            AFM13-preloaded cNK cells from healthy donors exhibited superior responses versus those from Hodgkin lymphoma patients suggesting that the source of NK cells impacts tumor cell killing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AFM13-NK cells,Cyclophosphamide,Fludarabine Phosphate

            Therapeutic Area: Oncology Product Name: AFM13-NK cells

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            First in human study to combine an NK cell product with an antibody whose primary mechanism is designed to specifically bind and activate NK cells and tumors cells in a bispecific fashion.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BI 905711

            Therapeutic Area: Oncology Product Name: BI 905711

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 10, 2020

            Details:

            The first-in-class BI 905711 antibody is designed to recognize both the pro-apoptotic TNF-related apoptosis-inducing ligand receptor 2 and the tumor cell anchor CDH17 to activate apoptosis pathway in co-expressing tumor cells found mostly in the GI tract.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMA202

            Therapeutic Area: Oncology Product Name: IMA202

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 18, 2020

            Details:

            First patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by FDA) approval by Paul-Ehrlich-Institute (PEI), the regulatory body for cell and gene therapies in Germany.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tinostamustine

            Therapeutic Area: Oncology Product Name: EDO-S101

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 04, 2020

            Details:

            Tinostamustine is in early phase clinical trials (Phase I) to investigate its use as a potential future treatment option in this area of significant unmet patient need.Tinostamustine is the only medicinal product with an orphan drug designation for T-PLL in the EU.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT111

            Therapeutic Area: Oncology Product Name: BNT111

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 30, 2020

            Details:

            Safety assessment was performed in 89 advanced melanoma patients treated with intravenously delivered repeated doses of mRNA-based cancer vaccine BNT111 ranging from 7.2µg to 400µg. Overall, BNT111 treatment was well tolerated with no dose limiting toxicity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MDG1021

            Therapeutic Area: Oncology Product Name: MDG1021

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2020

            Details:

            The Phase I study of MDG1021 will be initiated at the Leiden University Medical Center (LUMC), the Netherlands, and will enroll patients suffering from relapsed or persistent blood cancers after allogeneic (non-self) hematopoietic stem cell transplantation